The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Ngm Biopharmaceuticals Inc shares valued at $3,627 were purchased by COLUMN GROUP L P on Nov 16 ’23. At $0.62 per share, COLUMN GROUP L P acquired 5,840 shares. The insider’s holdings grew to 949,862 shares worth approximately $1.54 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, COLUMN GROUP L P purchased 5,840 shares, netting a total of over 3,627 in proceeds. Following the buying of shares at $0.62 each, the insider now holds 949,862 shares.
Before that, COLUMN GROUP L P had added 5,840 shares to its account. In a trade valued at $3,627, the Director bought Ngm Biopharmaceuticals Inc shares for $0.62 each. Upon closing the transaction, the insider’s holdings increased to 5,840 shares, worth approximately $1.54 million.
As published in a research note from Raymond James on March 12, 2024, Ngm Biopharmaceuticals Inc [NGM] has been rated down from an Outperform to a Mkt perform. Analysts at TD Cowen downgraded the stock from ‘”an Outperform”‘ to ‘”a Market perform”‘ outlook in a report released in late February. As of February 27, 2024, Citigroup has decreased its “Buy” rating to a “Neutral” for NGM. Earlier on May 03, 2023, Citigroup initiated its rating. Their recommendation was “a Buy” for NGM stock.
Analyzing NGM Stock Performance
During the last five days, there has been a surge of approximately 4.52%. Over the course of the year, Ngm Biopharmaceuticals Inc shares have jumped approximately 88.59%. Shares of the company reached a 52-week high of $2.2000 on 02/22/24 and a 52-week low of $1.0100 on 01/02/24. A 50-day SMA is recorded $1.5187, while a 200-day SMA reached $1.5900. Nevertheless, trading volume fell to 3.3 million shares from 1.36 million shares the previous day.
Support And Resistance Levels for Ngm Biopharmaceuticals Inc (NGM)
According to the 24-hour chart, there is a support level at 1.5567, which, if violated, would cause prices to drop to 1.4933. In the upper region, resistance lies at 1.6567. The next price resistance is at 1.6933. RSI (Relative Strength Index) is 60.38 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0205, which suggests the price will decrease in the coming days. Percent R is at 9.09%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Ngm Biopharmaceuticals Inc subject to short interest?
Stocks of Ngm Biopharmaceuticals Inc saw a sharp steep in short interest on Feb 29, 2024 dropping by 50000.0 shares to 1.63 million. Data from Yahoo Finance shows that the short interest on Jan 31, 2024 was 1.68 million shares. A decline of -3.07% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 1.52 of the overall float, the days-to-cover ratio (short ratio) decline to 1.52.
